Novartis Sneaks Ahead Of Sanofi To Buy Gyroscope
Pays $800m Upfront For Gene Therapy Eye Specialist
The Swiss giant is paying up to $1.5bn upfront to get hold of Gyroscope's AAV2-based one-time investigational gene therapy for geographic atrophy, an advanced form of dry AMD that leads to irreversible vision loss.
